Drug development platform creator Xbiome has raised nearly $100m in series B funding while bioindustrial startup services provider 21st.Bio secured a similar amount from Novo.

Funding

Xbiome, the China-based creator of an artificial intelligence-equipped drug development platform, has raised almost $100m in a series B round featuring Legend Capital, the venture capital firm established by conglomerate Legend Holdings. It was joined in the round by 5Y Capital, Primavera Capital, Gaorong Capital and Hike Capital.

Pharmaceutical firm Novo has provided €86m ($97.2m) in funding for 21st.Bio, a Denmark-based provider of scale-up services for bioindustrial startups. The company has also licensed technology from bioinnovation technology producer Novozymes.

…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn